Therapeutic and prophylactic effects of romurtide against experimental animal infections.
Niki
Y
Y
Department of Primary Health Care and Preventive Medicine, Kawasaki Medical School, Japan.
Tatara
O
O
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000666:Amphotericin B / Q000008:administration & dosage; D000818:Animals; D001228:Aspergillosis / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D001232:Aspergillus fumigatus; D015281:Cefmenoxime / Q000008:administration & dosage; D004195:Disease Models, Animal; D016867:Immunocompromised Host; D007710:Klebsiella Infections / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D007711:Klebsiella pneumoniae; D008172:Lung Diseases, Fungal / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D008297:Male; D051379:Mice; D011014:Pneumonia / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D051381:Rats
D000276:Adjuvants, Immunologic; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D000666:Amphotericin B; D015281:Cefmenoxime; C036866:romurtide